Bulletin
Investor Alert

New York Markets Open in:

press release

March 2, 2021, 7:01 a.m. EST

Bio-Techne To Present At The Barclays Global Healthcare Conference

MINNEAPOLIS, March 2, 2021 /PRNewswire/ -- Bio-Techne Corporation /zigman2/quotes/203973516/composite TECH +2.90% today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 9:10 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar .

Bio-Techne Corporation /zigman2/quotes/203973516/composite TECH +2.90% is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx [®]  Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide.

Contact: David Clair, Senior Director, Investor Relations & Corporate Development

david.clair@bio-techne.com

612-656-4416  

 

 

Cision
View original content to download multimedia: http://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-barclays-global-healthcare-conference-301238242.html

SOURCE Bio-Techne Corporation

COMTEX_381988796/2454/2021-03-02T07:00:53

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 PR Newswire. All rights reserved

/zigman2/quotes/203973516/composite
US : U.S.: Nasdaq
$ 423.84
+11.93 +2.90%
Volume: 236,809
April 21, 2021 4:00p
P/E Ratio
96.65
Dividend Yield
0.30%
Market Cap
$15.98 billion
Rev. per Employee
$321,170
loading...
/zigman2/quotes/203973516/composite
US : U.S.: Nasdaq
$ 423.84
+11.93 +2.90%
Volume: 236,809
April 21, 2021 4:00p
P/E Ratio
96.65
Dividend Yield
0.30%
Market Cap
$15.98 billion
Rev. per Employee
$321,170
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.